These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16217228)

  • 1. Cardiac rehabilitation and getting to lipid goals.
    Wilson PW
    J Cardiopulm Rehabil; 2005; 25(5):264-5. PubMed ID: 16217228
    [No Abstract]   [Full Text] [Related]  

  • 2. Independent effect of cardiac rehabilitation on lipids in coronary artery disease.
    Snow R; LaLonde M; Hindman L; Falko J; Caulin-Glaser T
    J Cardiopulm Rehabil; 2005; 25(5):257-61; quiz 262-3. PubMed ID: 16217226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome.
    Davidson MH
    Am J Cardiol; 2004 Jun; 93(11A):3C-11C. PubMed ID: 15178511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the National Cholesterol Education Program Adult Treatment Panel III guidelines: getting to goal.
    McKenney JM
    Pharmacotherapy; 2003 Sep; 23(9 Pt 2):26S-33S. PubMed ID: 14524636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the management of hyperlipidemia-induced atherosclerosis.
    Tannock LR
    Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):369-83. PubMed ID: 18327996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid disorders.
    Kole LA
    JAAPA; 2009 Nov; 22(11):54-5. PubMed ID: 19999177
    [No Abstract]   [Full Text] [Related]  

  • 7. Should we change our lipid management strategies to focus on non-high-density lipoprotein cholesterol?
    Rana JS; Boekholdt SM
    Curr Opin Cardiol; 2010 Nov; 25(6):622-6. PubMed ID: 20852414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New targets for medical treatment of lipid disorders.
    Brousseau ME; Schaefer EJ
    Curr Atheroscler Rep; 2002 Sep; 4(5):343-9. PubMed ID: 12162933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy.
    Farnier M; Ducobu J; Bryniarski L
    Am J Cardiol; 2010 Sep; 106(6):787-92. PubMed ID: 20816118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of raising high-density lipoprotein cholesterol for prevention of coronary heart disease.
    Teramoto T
    Curr Atheroscler Rep; 2002 Sep; 4(5):327-8. PubMed ID: 12162930
    [No Abstract]   [Full Text] [Related]  

  • 11. Changing face of dyslipidemia therapy.
    Banerjee AK
    Indian Heart J; 2008; 60(3):192-4. PubMed ID: 19240305
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
    Duvall WL; Blazing MA; Saxena S; Guyton JR
    J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the management of dyslipidemia.
    Irons BK; Snella KA; McCall K; MacLaughlin EJ; Villarreal M
    Am J Health Syst Pharm; 2002 Sep; 59(17):1615-25. PubMed ID: 12224342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins.
    Devroey D; Velkeniers B; Duquet W; Betz W
    Acta Cardiol; 2003 Jun; 58(3):179-84. PubMed ID: 12846506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk.
    Brown BG; Zhao XQ
    Am J Cardiol; 2008 Apr; 101(8A):58B-62B. PubMed ID: 18375243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal lipid screening and use of lipid-lowering medications in pediatric type 1 diabetes.
    Maahs DM; Wadwa RP; McFann K; Nadeau K; Williams MR; Eckel RH; Klingensmith GJ
    J Pediatr; 2007 Feb; 150(2):146-50, 150.e1-2. PubMed ID: 17236891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taking aim at HDL-C. Raising levels to reduce cardiovascular risk.
    McGovern ME
    Postgrad Med; 2005 Apr; 117(4):29-30, 33-5, 39 passim. PubMed ID: 15842130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing high-density lipoprotein cholesterol: an update on fenofibrate.
    Després JP
    Am J Cardiol; 2001 Dec; 88(12A):30N-36N. PubMed ID: 11788128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease.
    Karalis DG; Ross AM; Vacari RM; Zarren H; Scott R
    Am J Cardiol; 2002 Mar; 89(6):667-71. PubMed ID: 11897207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.